Burroughs Wellcome’s Alkeran I.V.
Executive Summary
New dosage form of melphalan approved Nov. 18 for second-line treatment of multiple myeloma; first shipments will begin in March. Alkeran is already approved in tablet form as first-line multiple myeloma therapy. In January, FDA's Oncologic Drugs Advisory Committee recommended second-line status for the I.V. form due to possible hypersensitivity.